Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.

Abstract

Dazopride, a substituted benzamide structurally related to metoclopramide, is a potent gastric prokinetic agent that prevents cisplatin-induced emesis in animals. Unlike metoclopramide, dazopride has no effect on dopamine receptors and therefore should not produce extrapyramidal side effects. In this dose-ranging trial, 23 patients with cancer receiving chemotherapy known to produce nausea and vomiting received three i.v. infusions of dazopride every 2 h beginning 30 min before the chemotherapy. Seven dose levels were explored ranging from 0.5 to 4.0 mg/kg in each of the three infusions. Toxicities were mild and included sedation, dizziness, visual disturbances, and headaches. All side effects were transient and were not dose-related. Antiemetic effects were observed. Dazopride can be safely given on this schedule at doses of up to 4.0 mg/kg to patients receiving chemotherapy. On the basis of the results of this trial, further studies of this agent are warranted.

• Authors: S C Grant, M G Kris, R J Gralla, R A Clark, L B Tyson
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 31 Issue 6 Pg. 442-4 ( 1993) ISSN: 0344-5704 [Print] Germany
• PMID: 8453682 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antiemetics
• Benzamides
• dazopride

Topics

• Adult
• Aged
• Antiemetics (administration & dosage, adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Benzamides (administration & dosage, adverse effects)
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Treatment Outcome
• Vomiting (chemically induced, prevention & control)